AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparietal corrected diameters moderate abnormal
Number of subjects: 114
Study 34661885 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD
Number of subjects: 0
Study 34661885 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg QD
Number of subjects: 0
Study 34661885 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 34661885 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg QD and 30 mg QD
Number of subjects: 0
Study 34661903 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 µg/d (FA400)
Number of subjects: 822
Study 34661903 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 800 µg/d (FA800)
Number of subjects: 822
Study 34661903 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 µg/d (FA400) plus creatine (3 g/d)
Number of subjects: 822
Study 34662125 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-targeted PET radioligand
Number of subjects: 0
Study 34662285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) delivered via telemental health; details on dosage and duration not specified.
Number of subjects: 0
Study 34662285 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control intervention not available.
Number of subjects: 0
Study 34662378 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) based on a 9-cellular component model reflecting tumor microenvironment (TME) composition.
Number of subjects: 246
Study 34662523 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Near-Infrared Light 1068 nm
Number of subjects: 0
Study 34662778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate + glutamine (Glx) levels in the dorsal anterior cingulate cortex (dACC)
Number of subjects: 70
Study 34662778 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive resting state functional connectivity (FC) of the salience network (SN)
Number of subjects: 70
Study 34662778 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative resting state functional connectivity (FC) of the salience network (SN)
Number of subjects: 70
Study 34662778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glx-FC associations in the salience network (SN)
Number of subjects: 70
Study 34662778 — intervention group
Group type: COMPARATOR
Intervention: Glx levels in healthy controls (HC)
Number of subjects: 70
Study 34662778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glx levels in first episode psychosis (FEP)
Number of subjects: 70
Study 34662857 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Lung Ultrasound Score (LUS)
Number of subjects: 137
Study 34662857 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpleural consolidation and pleural line abnormalities
Number of subjects: 137
Study 34662857 — intervention group
Group type: EXPERIMENTAL
Intervention: Examinations within 24 hours of intubation
Number of subjects: 137
Study 34663154 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 543
Study 34663154 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 543
Study 34663154 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcers
Number of subjects: 543
Study 34663193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-intensity interval training circuit (HIIT)
Number of subjects: 55
Study 34663193 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 55
Study 34663208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST)
Number of subjects: 19
Study 34663208 — intervention group
Group type: EXPERIMENTAL
Intervention: UST trough concentration > 1.12 μg/mL
Number of subjects: 19
Study 34663224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided automated spinal landmark identification program
Number of subjects: 48
Study 34663254 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET-CT
Number of subjects: 156
Study 34663254 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging (CT/MRI)
Number of subjects: 156
Study 34663435 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Imaging Stewardship (PCIS) intervention, which includes audit and feedback, academic detailing, and Clinical Order Check.
Number of subjects: 0
Study 34663435 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implies standard practice without the intervention.
Number of subjects: 0
Study 34663439 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-based digital precision diagnostics combined with standard-of-care microbiological analyses
Number of subjects: 410
Study 34663439 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care microbiological analyses
Number of subjects: 410
Study 34663474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 21
Study 34663474 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling (sham DN)
Number of subjects: 21
Study 34663479 — intervention group
Group type: EXPERIMENTAL
Intervention: High lactate clearance (HLC) group (initial 24 h LC ≥ 64%, n = 333)
Number of subjects: 628
Study 34663479 — intervention group
Group type: COMPARATOR
Intervention: Low lactate clearance (LLC) group (n = 295)
Number of subjects: 628
Study 34663479 — intervention group
Group type: EXPERIMENTAL
Intervention: HLC group
Number of subjects: 628
Study 34663479 — intervention group
Group type: COMPARATOR
Intervention: LLC group
Number of subjects: 628
Study 34663479 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial serum lactate > 5 mmol/L
Number of subjects: 628
Study 34663479 — intervention group
Group type: COMPARATOR
Intervention: Initial serum lactate ≤ 5 mmol/L
Number of subjects: 628
Study 34663588 — intervention group
Group type: EXPERIMENTAL
Intervention: DRAUP deimplementation programme
Number of subjects: 0
Study 34663638 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (75 mg intravenous) plus Durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by Durvalumab maintenance every 4 weeks (up to nine doses)
Number of subjects: 26
Study 34663638 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment evaluation of the bone microenvironment
Number of subjects: 26
Study 34663640 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 153
Study 34663650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation programme (including physical, occupational, and speech therapy)
Number of subjects: 0
Study 34663657 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CCTA)
Number of subjects: 0
Study 34663687 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34663746 — intervention group
Group type: EXPERIMENTAL
Intervention: PREFER-HF trial
Number of subjects: 3000
Study 34664183 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon (ethinylestradiol 30 μg and levonorgestrel 150 μg) administered before nintedanib and after nintedanib 150 mg twice daily for ≥ 10 consecutive days.
Number of subjects: 15
Study 34664224 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation
Number of subjects: 62
Study 34664427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen (75 mg)
Number of subjects: 0
Study 34664427 — intervention group
Group type: EXPERIMENTAL
Intervention: Mevidalen (titration from 15 to 75 mg)
Number of subjects: 0
Study 34664427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34664531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide PRF (prolonged-release formulation) administered every 12 weeks
Number of subjects: 9
Study 34664531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide PRF
Number of subjects: 9
Study 34664789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1051)
Number of subjects: 3275
Study 34664789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 641)
Number of subjects: 3275
Study 34664789 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1087)
Number of subjects: 3275
Study 34664789 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 496)
Number of subjects: 3275
Study 34665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-based treatment
Number of subjects: 0
Study 34665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profile and genetic mutations comparison
Number of subjects: 0
Study 34665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related gene expression and diversity
Number of subjects: 0
Study 34665002 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers for cancer relapse, diagnosis, and prognosis
Number of subjects: 0
Study 34665133 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted finger movements
Number of subjects: 0
Study 34665133 — intervention group
Group type: EXPERIMENTAL
Intervention: Years since SCI
Number of subjects: 0
Study 34665142 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Multimedia Interactive Informed Consent (VIC)
Number of subjects: 50
Study 34665142 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper consent
Number of subjects: 50
Study 34665631 — intervention group
Group type: EXPERIMENTAL
Intervention: CHK1 Inhibitor Candidate (specific dosage and duration not mentioned)
Number of subjects: 0
Study 34665659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Ultrasound Guidance in Stenting
Number of subjects: 0
Study 34665659 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34665780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracortical microelectrode array stimulation (96 electrodes)
Number of subjects: 1
Study 34665780 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation via multiple electrodes
Number of subjects: 1
Study 34665781 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB5+ MSCs (2 × 10^6 cells/kg) administered via 3 i.v. infusions on days 0, 17, and 35
Number of subjects: 16
Study 34665810 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400 mg oral dose of Albendazole (ALB)
Number of subjects: 645
Study 34665942 — intervention group
Group type: EXPERIMENTAL
Intervention: RC48 2.5 mg/kg alone every 2 weeks
Number of subjects: 125
Study 34666197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level activity group (≥5000 steps/d)
Number of subjects: 134
Study 34666197 — intervention group
Group type: COMPARATOR
Intervention: Low-level activity group (<5000 steps/d)
Number of subjects: 134
Study 34666197 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity level <3500 steps/d
Number of subjects: 134
Study 34666197 — intervention group
Group type: COMPARATOR
Intervention: Activity level ≥3500 steps/d
Number of subjects: 134
Study 34666197 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm deliveries
Number of subjects: 134
Study 34666214 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with regional hyperthermia
Number of subjects: 109
Study 34666214 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 109
Study 34666344 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy
Number of subjects: 173
Study 34666347 — intervention group
Group type: EXPERIMENTAL
Intervention: CD30 CAR T-cell therapy (CD30.CAR-T)
Number of subjects: 27
Study 34666347 — intervention group
Group type: EXPERIMENTAL
Intervention: High metabolic tumor volume (MTV > 60 mL) before lymphodepletion and CD30.CAR-T infusion
Number of subjects: 27
Study 34666347 — intervention group
Group type: COMPARATOR
Intervention: Bridging therapy
Number of subjects: 27
Study 34666347 — intervention group
Group type: COMPARATOR
Intervention: Response to bridging therapy
Number of subjects: 27
Study 34666347 — intervention group
Group type: COMPARATOR
Intervention: CD30.CAR-T expansion/persistence
Number of subjects: 27
Study 34666347 — intervention group
Group type: COMPARATOR
Intervention: Percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy
Number of subjects: 27
Study 34666347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 27
Study 34666382 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal surface electrode patch
Number of subjects: 30
Study 34666382 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound monitoring
Number of subjects: 30
Study 34666500 — intervention group
Group type: EXPERIMENTAL
Intervention: CEC adjudication
Number of subjects: 3457
Study 34666500 — intervention group
Group type: COMPARATOR
Intervention: QFR analysis
Number of subjects: 3457
Study 34666500 — intervention group
Group type: COMPARATOR
Intervention: Agreement between CEC and QFR
Number of subjects: 3457
Study 34666500 — intervention group
Group type: COMPARATOR
Intervention: Overall concordance and discordance rates
Number of subjects: 3457
Study 34666509 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with preserved EF
Number of subjects: 6145
Study 34666509 — intervention group
Group type: EXPERIMENTAL
Intervention: HF with reduced EF
Number of subjects: 6145
Study 34666711 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning (ACP) intervention during visits 2 and 3
Number of subjects: 0
Study 34666709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonagenarians (age > 90 years)
Number of subjects: 7900
Study 34666709 — intervention group
Group type: COMPARATOR
Intervention: Octogenarians (age 80-89.9 years)
Number of subjects: 7900
Study 34666778 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside the window group (IW) with platelet reactivity (PR) between 25.5-37.4%
Number of subjects: 1885
Study 34666778 — intervention group
Group type: COMPARATOR
Intervention: Outside the window group (OW) with PR < 25.5% or > 37.4%
Number of subjects: 1885
Study 34666820 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 284
Study 34666820 — intervention group
Group type: COMPARATOR
Intervention: Standard care (non-invasive ventilation)
Number of subjects: 284
Study 34666839 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically oriented resilience intervention (7-week group-based program)
Number of subjects: 60
Study 34667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 5681
Study 34667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 5681
Study 34667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Male snowboarders wearing a helmet
Number of subjects: 5681
Study 34667014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome of severe or fatal injuries
Number of subjects: 5681
Study 34667082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 215
Study 34667082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS) in patients with probable RBD (pre-opRBD+)
Number of subjects: 215
Study 34667082 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS) in patients without probable RBD (pre-opRBD-)
Number of subjects: 215
Study 34667843 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-42
Number of subjects: 11
Study 34667919 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN) device for 4 weeks
Number of subjects: 126
Study 34668047 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised mobilization performed by a specialized physiotherapist using a modified Surgical ICU Optimal Mobilization Score (SOMS)
Number of subjects: 42
Study 34668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) referral with active telephone follow-up (ATF)
Number of subjects: 98
Study 34668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) referral without active telephone follow-up (ATF)
Number of subjects: 98
Study 34668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter referral with active telephone follow-up (ATF)
Number of subjects: 98
Study 34668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter referral without active telephone follow-up (ATF)
Number of subjects: 98
Study 34668873 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of letter vs POC referrals
Number of subjects: 98
Study 34668873 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving ATF
Number of subjects: 98
Study 34668873 — intervention group
Group type: COMPARATOR
Intervention: Recruitment costs
Number of subjects: 98
Study 34668977 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab at 200 mg IV Q2W
Number of subjects: 146
Study 34669164 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular, twice-weekly voluntary PCR testing of health-care workers (HCW) and visitors in interventional nursing homes (INH)
Number of subjects: 3150
Study 34669164 — intervention group
Group type: COMPARATOR
Intervention: No regular testing in control nursing homes (CNH)
Number of subjects: 3150
Study 34669179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg once daily
Number of subjects: 0
Study 34669179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg once daily
Number of subjects: 0
Study 34669183 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI; Acthar) 80 U subcutaneously twice weekly for 12 weeks followed by a 4-week taper
Number of subjects: 35
Study 34669644 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconsultation for preoperative evaluation
Number of subjects: 111
Study 34669959 — intervention group
Group type: EXPERIMENTAL
Intervention: Durum wheat semolina spaghetti
Number of subjects: 30
Study 34669959 — intervention group
Group type: EXPERIMENTAL
Intervention: Penne
Number of subjects: 30
Study 34669959 — intervention group
Group type: COMPARATOR
Intervention: Couscous
Number of subjects: 30
Study 34669959 — intervention group
Group type: COMPARATOR
Intervention: Bread
Number of subjects: 30
Study 34669959 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaghetti
Number of subjects: 30
Study 34669990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 0
Study 34669990 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 34669990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34670025 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation Magnetic Seizure Therapy
Number of subjects: 0
Study 34670027 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34670028 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-Compulsive Personality Disorder
Number of subjects: 0
Study 34670043 — intervention group
Group type: COMPARATOR
Intervention: Stage F0 to F2 fibrosis
Number of subjects: 1773
Study 34670043 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage F3 fibrosis
Number of subjects: 1773
Study 34670043 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage F4 fibrosis
Number of subjects: 1773
Study 34670043 — intervention group
Group type: EXPERIMENTAL
Intervention: Any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy)
Number of subjects: 1773
Study 34670118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau transgenic mice
Number of subjects: 0
Study 34670148 — intervention group
Group type: EXPERIMENTAL
Intervention: MFCNN algorithm trained with 100 IVUS pullbacks (8427 manually segmented frames)
Number of subjects: 63
Study 34670169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab maintenance therapy after ASCT
Number of subjects: 144
Study 34670169 — intervention group
Group type: COMPARATOR
Intervention: Control group (ASCT without pembrolizumab maintenance)
Number of subjects: 144
Study 34670385 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based nutrition score
Number of subjects: 69
Study 34670385 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based noncardiovascular score
Number of subjects: 69
Study 34670385 — intervention group
Group type: EXPERIMENTAL
Intervention: GNRI <91
Number of subjects: 69
Study 34670443 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet Quality Index for Adolescents (DQI-A)
Number of subjects: 238
Study 34670443 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Questionnaire for Older Children (PAQ-C)
Number of subjects: 238
Study 34670443 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking habits
Number of subjects: 238
Study 34670443 — intervention group
Group type: EXPERIMENTAL
Intervention: Child- and environment-associated determinants
Number of subjects: 238
Study 34670443 — intervention group
Group type: COMPARATOR
Intervention: Parents-associated determinants
Number of subjects: 238
Study 34670475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low whole blood viscosity (WBV) in elective PCI patients
Number of subjects: 500
Study 34670475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient group
Number of subjects: 500
Study 34670475 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMI group
Number of subjects: 500
Study 34670475 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-STEMI group
Number of subjects: 500
Study 34670475 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective PCI group
Number of subjects: 500
Study 34670521 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminder (after 2 and 3 weeks via email, and postal reminders after 4 weeks, followed by telephone contact with a maximum of two attempts)
Number of subjects: 812
Study 34670521 — intervention group
Group type: COMPARATOR
Intervention: No telephone reminder (Group 3: non-respondents)
Number of subjects: 812
Study 34670560 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring perceptions, behaviours, and attitudes towards smoking.
Number of subjects: 25
Study 34670600 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive helping (psychological intervention including emotionally expressive writing and peer support writing)
Number of subjects: 0